What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Some observational studies have found that antidepressant use was associated with survival differences in particular cancer groups, but the findings are mixed and do not show that the drugs treat cancer or help people live longer. Antidepressants should not be started, stopped, or changed to influence cancer outcomes. Decisions about treating depression are separate and should be made with a clinician.
What studies have found about antidepressants and cancer survival
The evidence is not a single, consistent result. Studies examine different cancers, antidepressant classes, treatment timings, and measures of survival. Most of the survival findings described here come from observational studies, which can identify associations but cannot establish that a medication caused an outcome.
| Study and population | Exposure and outcome | Finding | What it can establish |
|---|---|---|---|
| 2017 NCI-Maryland lung-cancer study; 1,097 patients | Antidepressant use and lung-cancer-specific survival | Use was associated with longer cancer-specific survival; class-specific analyses reported associations for NDRIs and TCAs. | An association in this study population, not proof of a treatment effect. |
| 2026 ASCO meeting abstract; propensity-matched lung-cancer immunotherapy cohort | Baseline SSRI/SNRI use and overall survival | Median overall survival was 671 versus 665 days; HR 1.01 (95% CI 0.97–1.04). | The abstract reported no overall-survival difference associated with baseline SSRI/SNRI use in this cohort. It was not a randomized test of antidepressants as cancer treatment. |
| 2023 JAMA Network Open hepatocellular-carcinoma cohort | Antidepressant use before or after diagnosis and mortality | Use before diagnosis was not associated with lower cancer-specific mortality after adjustment (HR 1.06, 95% CI 0.96–1.17). Use after diagnosis was associated with lower overall and cancer-specific mortality. | Different associations by timing, not evidence that postdiagnosis medication caused lower mortality. |
How to interpret the individual findings
Lung cancer: an earlier association and a later null result
The 2017 analysis of 1,097 patients in the NCI-Maryland lung-cancer study reported an association between antidepressant use and extended lung-cancer-specific survival. Its class-specific analyses reported associations for norepinephrine and dopamine reuptake inhibitors (NDRIs) and tricyclic antidepressants (TCAs). The authors raised a possible direct effect on lung-cancer biology, but that explanation remains a hypothesis: the observational study could not separate a medication effect from other differences between patients.
A 2026 ASCO meeting abstract examined baseline selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) use in a propensity-matched real-world cohort of people with lung cancer receiving immune-checkpoint inhibitors. The reported median overall survival was 671 days for users and 665 days for nonusers; the hazard ratio was 1.01 (95% CI 0.97–1.04), indicating no overall-survival difference in that analysis. This conference abstract addresses a particular drug grouping and treatment setting; it does not settle every question about antidepressants, other cancers, or other timings of use.
Liver cancer: timing was associated with different results
In a 2023 JAMA Network Open observational cohort of people with hepatocellular carcinoma, antidepressant use before diagnosis was not associated with lower cancer-specific mortality after adjustment. Use after diagnosis was associated with lower overall and cancer-specific mortality. Because treatment was not randomly assigned, the postdiagnosis association could reflect differences in patients, cancer care, treatment, or other factors. The contrast is a reason to pay attention to when medication use was measured—not a basis for concluding that starting an antidepressant after diagnosis improves survival.
Why observational survival results cannot prove a cancer benefit
People who take antidepressants may differ from those who do not in ways that also affect survival. Cancer type, care received, other health conditions, depression, and the timing of treatment are among the factors that can complicate comparisons. Statistical adjustment or matching can account for measured differences, but it cannot guarantee that all relevant differences have been captured.
Rank #2
It also matters which outcome a study measures. Overall survival counts death from any cause; cancer-specific survival or mortality focuses on deaths attributed to cancer. A finding about one is not automatically a finding about the other. Likewise, evidence about depressive symptoms does not answer whether a drug affects cancer survival.
- Check the cancer population and treatment setting rather than treating one cancer study as applicable to all cancers.
- Look at whether medication use was measured before diagnosis or after it, and which antidepressant classes were included.
- Distinguish overall survival, cancer-specific survival, and depression-symptom outcomes.
- Note whether a result comes from a randomized trial, an observational cohort, or a conference abstract, and consider the uncertainty around its estimate.
Depression treatment in cancer care is a separate question
A 2023 Cochrane review included 14 studies and 1,364 participants with cancer. It concluded that antidepressants may reduce depressive symptoms over six to 12 weeks, but rated the evidence very low certainty. The review did not establish that antidepressants extend cancer survival and said their use in people with cancer should be considered individually.
Rank #3
Depression itself and survival have also been studied separately. A 2021 University College London study of 20,582 people with breast, colorectal, gynecological, lung, or prostate cancer found that major depression was associated with worse survival across those cancer groups; the pooled hazard ratio was 1.41 (95% CI 1.29–1.54). That association does not show that antidepressants reverse the association or improve cancer outcomes.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What to do if you or someone you care for has cancer
Do not start, stop, or change an antidepressant to try to affect cancer survival. If depression symptoms are affecting daily life, discuss them with the oncology team, primary-care clinician, or mental-health professional. They can consider the person’s symptoms, current medicines, cancer care, and preferences when discussing treatment. The decision to treat depression should not be presented as a cancer-survival strategy.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
